Advertisements


Technical Take: Alkermes jumps after FDA rescinds Refusal to File letter

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

FDA rescinds Refusal to File letter for Alkermes depression drug

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Technical Take: Alkermes drops on FDA Refusal to File letter

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2018

Alkermes Receives Refusal To File Letter From The FDA, Is There Any Hope?

Alkermes Receives Refusal To File Letter From The FDA, Is There Any Hope?.....»»

Category: topSource: seekingalphaApr 6th, 2018

Alkermes Sinks as FDA Refuses Depression Drug Review

Alkermes (ALKS) shares declined by more than 21% as it received a Refusal to File letter from the FDA for its pipeline candidate, ALKS 5461, which was.....»»

Category: worldSource: nytApr 3rd, 2018

FDA Gets Down on Alkermes Depression Drug

Alkermes saw its shares drop early on Monday after the company announced that it received a Refusal to File letter from the FDA......»»

Category: blogSource: 247wallstApr 2nd, 2018

Alkermes received Refusal to File letter on Friday night, CEO says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2018

Alkermes Falls 20% After FDA Refusal To File Letter

Shares of Alkermes Plc (NASDAQ: ALKS) lost more than 20 percent early Monday morning after the U.S. Food and Drug Administration said it won't review the company's therapy ALKS-5461. read more.....»»

Category: blogSource: benzingaApr 2nd, 2018

Alkermes shares drop 16%, or $9.21, to $48.75 following Refusal to File letter

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2018

Intra-Cellular drops 9% after Alkermes receives Refusal to File letter

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2018

Alkermes announces FDA Refusal to File letter received for ALKS 5461

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2018

Alkermes announces FDA Refusal to File letter received for ALKS 5461

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2018

Evercore ISI says Alkermes likely to open in "high $40s" after Refusal to File

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2018

Alkermes shares tumble 22% after FDA "refusal" letter for depression treatment

Alkermes .....»»

Category: topSource: marketwatchApr 2nd, 2018

Alkermes receives FDA refusal letter regarding NDA for treatment of depressive disorder

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 2nd, 2018

Alkermes" stock resumes trade, tumbles 19% premarket after FDA "refusal" letter

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 2nd, 2018

Why the Celgene Damage May Be an Overreaction

Celgene watched its shares drop on Wednesday after the company announced that it received a Refusal to File letter from the FDA......»»

Category: blogSource: 247wallstFeb 28th, 2018

SunTrust downgrades Celgene on refusal to file letter for ozanimod

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 28th, 2018

Celgene receives Refusal to File letter from FDA regarding ozanimod NDA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 27th, 2018

FDA Crushes SteadyMed With Refusal to File Letter

SteadyMed shares plummeted after the firm had a setback from the FDA regarding its pulmonary arterial hypertension treatment......»»

Category: blogSource: 247wallstAug 31st, 2017

Acorda stock plummets 26% on ‘surprising, puzzling, disconcerting’ FDA drug decision

A refusal to file letter means that the company’s drug application wasn’t complete enough and is considered embarrassing for a drug company......»»

Category: topSource: marketwatchAug 29th, 2017